CN102471295A - 由不良溶剂添加法制造2-(3-氰基-4-异丁基氧基苯基)-4-甲基-5-噻唑羧酸的结晶多晶型物的方法 - Google Patents
由不良溶剂添加法制造2-(3-氰基-4-异丁基氧基苯基)-4-甲基-5-噻唑羧酸的结晶多晶型物的方法 Download PDFInfo
- Publication number
- CN102471295A CN102471295A CN2010800323972A CN201080032397A CN102471295A CN 102471295 A CN102471295 A CN 102471295A CN 2010800323972 A CN2010800323972 A CN 2010800323972A CN 201080032397 A CN201080032397 A CN 201080032397A CN 102471295 A CN102471295 A CN 102471295A
- Authority
- CN
- China
- Prior art keywords
- crystallization
- methyl
- solvent
- isobutyl
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002904 solvent Substances 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 28
- 239000013078 crystal Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 21
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 10
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 10
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 20
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 abstract description 8
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 abstract 2
- 238000002425 crystallisation Methods 0.000 description 53
- 230000008025 crystallization Effects 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000001035 drying Methods 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 230000006399 behavior Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 150000007979 thiazole derivatives Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- ZGWGSEUMABQEMD-UHFFFAOYSA-N 4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC=1N=CSC=1C(O)=O ZGWGSEUMABQEMD-UHFFFAOYSA-N 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009166755 | 2009-07-15 | ||
JP2009-166755 | 2009-07-15 | ||
PCT/JP2010/062291 WO2011007895A1 (ja) | 2009-07-15 | 2010-07-14 | 貧溶媒添加法による2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102471295A true CN102471295A (zh) | 2012-05-23 |
CN102471295B CN102471295B (zh) | 2014-07-16 |
Family
ID=43449505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080032397.2A Expired - Fee Related CN102471295B (zh) | 2009-07-15 | 2010-07-14 | 由不良溶剂添加法制造2-(3-氰基-4-异丁基氧基苯基)-4-甲基-5-噻唑羧酸的结晶多晶型物的方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8735596B2 (zh) |
EP (1) | EP2455372B1 (zh) |
JP (1) | JP5654462B2 (zh) |
KR (1) | KR101645768B1 (zh) |
CN (1) | CN102471295B (zh) |
AU (1) | AU2010271717B2 (zh) |
BR (1) | BRPI1011671A2 (zh) |
CA (1) | CA2764603C (zh) |
ES (1) | ES2647239T3 (zh) |
IL (1) | IL217509A (zh) |
MX (1) | MX2011013946A (zh) |
RU (1) | RU2530895C2 (zh) |
SG (1) | SG177673A1 (zh) |
TW (1) | TWI516480B (zh) |
WO (1) | WO2011007895A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103588723A (zh) * | 2013-09-10 | 2014-02-19 | 杭州华东医药集团生物工程研究所有限公司 | 一种新型非布司他晶型a及其制备方法 |
CN103739568A (zh) * | 2014-02-07 | 2014-04-23 | 浙江普洛康裕制药有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法 |
CN103936688A (zh) * | 2013-01-21 | 2014-07-23 | 上海华拓医药科技发展股份有限公司 | 2-(3-氰基-4-(2-甲基丙氧基)苯基)-4-甲基-5-噻唑甲酸a晶的制备方法 |
CN106458970A (zh) * | 2014-05-13 | 2017-02-22 | 帝人制药株式会社 | 吡啶衍生物的新型多晶形体及其制造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2502920A1 (en) | 2011-03-25 | 2012-09-26 | Sandoz Ag | Crystallization process of Febuxostat from A |
CN102267957B (zh) * | 2011-08-24 | 2013-04-24 | 山东齐都药业有限公司 | 非布司他a晶型的制备方法 |
KR20180013563A (ko) * | 2016-07-29 | 2018-02-07 | 한미정밀화학주식회사 | 고순도 결정형 페북소스타트의 개선된 제조 방법 |
CN111499655B (zh) * | 2019-01-31 | 2023-01-06 | 华东理工大学 | 一种制备球形晶体的三液乳化溶剂扩散法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1275126A (zh) * | 1998-06-19 | 2000-11-29 | 帝人株式会社 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的多晶型体及其制备方法 |
WO2006115137A1 (ja) * | 2005-04-22 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | 2-アミノベンズイミダゾール誘導体及びその医薬用途 |
CN101139325A (zh) * | 2006-09-07 | 2008-03-12 | 上海医药工业研究院 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003261548A (ja) | 2002-03-07 | 2003-09-19 | Teijin Ltd | 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 |
CN101684107A (zh) * | 2008-09-26 | 2010-03-31 | 上海优拓医药科技有限公司 | 非布索坦的新晶型及其制备方法 |
CN101684108B (zh) * | 2009-04-15 | 2012-01-11 | 天津市汉康医药生物技术有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸及其组合物 |
KR20120140267A (ko) | 2009-06-10 | 2012-12-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | 페북소스타트의 결정형 |
-
2010
- 2010-07-14 BR BRPI1011671A patent/BRPI1011671A2/pt not_active Application Discontinuation
- 2010-07-14 JP JP2011522884A patent/JP5654462B2/ja not_active Expired - Fee Related
- 2010-07-14 WO PCT/JP2010/062291 patent/WO2011007895A1/ja active Application Filing
- 2010-07-14 KR KR1020127003728A patent/KR101645768B1/ko active IP Right Grant
- 2010-07-14 MX MX2011013946A patent/MX2011013946A/es active IP Right Grant
- 2010-07-14 AU AU2010271717A patent/AU2010271717B2/en not_active Ceased
- 2010-07-14 CN CN201080032397.2A patent/CN102471295B/zh not_active Expired - Fee Related
- 2010-07-14 EP EP10799952.6A patent/EP2455372B1/en active Active
- 2010-07-14 ES ES10799952.6T patent/ES2647239T3/es active Active
- 2010-07-14 CA CA2764603A patent/CA2764603C/en not_active Expired - Fee Related
- 2010-07-14 SG SG2012003059A patent/SG177673A1/en unknown
- 2010-07-14 RU RU2012105279/04A patent/RU2530895C2/ru not_active IP Right Cessation
- 2010-07-14 US US13/382,264 patent/US8735596B2/en active Active
- 2010-07-14 TW TW099123126A patent/TWI516480B/zh not_active IP Right Cessation
-
2012
- 2012-01-12 IL IL217509A patent/IL217509A/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1275126A (zh) * | 1998-06-19 | 2000-11-29 | 帝人株式会社 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的多晶型体及其制备方法 |
WO2006115137A1 (ja) * | 2005-04-22 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | 2-アミノベンズイミダゾール誘導体及びその医薬用途 |
CN101139325A (zh) * | 2006-09-07 | 2008-03-12 | 上海医药工业研究院 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法 |
Non-Patent Citations (2)
Title |
---|
ELISEO PASCUAL,等: "Febuxostat", 《NATURE REVIEWS DRUG DISCOVERY》 * |
唐春雷,等: "新型抗痛风药物非布索坦", 《中国新药杂志》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103936688A (zh) * | 2013-01-21 | 2014-07-23 | 上海华拓医药科技发展股份有限公司 | 2-(3-氰基-4-(2-甲基丙氧基)苯基)-4-甲基-5-噻唑甲酸a晶的制备方法 |
CN103588723A (zh) * | 2013-09-10 | 2014-02-19 | 杭州华东医药集团生物工程研究所有限公司 | 一种新型非布司他晶型a及其制备方法 |
CN103588723B (zh) * | 2013-09-10 | 2015-05-20 | 杭州华东医药集团新药研究院有限公司 | 一种非布司他晶型a的制备方法 |
CN103739568A (zh) * | 2014-02-07 | 2014-04-23 | 浙江普洛康裕制药有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法 |
CN103739568B (zh) * | 2014-02-07 | 2015-09-16 | 浙江普洛康裕制药有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法 |
CN106458970A (zh) * | 2014-05-13 | 2017-02-22 | 帝人制药株式会社 | 吡啶衍生物的新型多晶形体及其制造方法 |
CN106458970B (zh) * | 2014-05-13 | 2019-09-13 | 帝人制药株式会社 | 吡啶衍生物的多晶形体及其制造方法 |
Also Published As
Publication number | Publication date |
---|---|
BRPI1011671A2 (pt) | 2016-03-22 |
US8735596B2 (en) | 2014-05-27 |
JP5654462B2 (ja) | 2015-01-14 |
TWI516480B (zh) | 2016-01-11 |
CA2764603A1 (en) | 2011-01-20 |
CA2764603C (en) | 2017-03-14 |
MX2011013946A (es) | 2012-01-25 |
JPWO2011007895A1 (ja) | 2012-12-27 |
RU2530895C2 (ru) | 2014-10-20 |
SG177673A1 (en) | 2012-02-28 |
TW201118076A (en) | 2011-06-01 |
AU2010271717B2 (en) | 2014-11-27 |
AU2010271717A1 (en) | 2011-01-20 |
KR101645768B1 (ko) | 2016-08-04 |
WO2011007895A1 (ja) | 2011-01-20 |
EP2455372A4 (en) | 2012-12-05 |
RU2012105279A (ru) | 2013-08-20 |
EP2455372B1 (en) | 2017-10-11 |
IL217509A0 (en) | 2012-03-01 |
ES2647239T3 (es) | 2017-12-20 |
EP2455372A1 (en) | 2012-05-23 |
US20120108821A1 (en) | 2012-05-03 |
CN102471295B (zh) | 2014-07-16 |
IL217509A (en) | 2016-04-21 |
KR20120036363A (ko) | 2012-04-17 |
AU2010271717A8 (en) | 2012-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102471295B (zh) | 由不良溶剂添加法制造2-(3-氰基-4-异丁基氧基苯基)-4-甲基-5-噻唑羧酸的结晶多晶型物的方法 | |
CN105801645A (zh) | 制备索非布韦晶型6的方法 | |
CN111253406B (zh) | 一种医药中间体二氢苯并[4,5]咪唑并[1,2-a]嘧啶衍生物的制备方法 | |
JP5519201B2 (ja) | 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 | |
CN105646385A (zh) | 一种环丝氨酸的生产工艺 | |
CN112375039B (zh) | (r)-(+)-1-(1-苯乙基)-2-巯基咪唑-5-羧酸乙酯新晶型a及制备方法 | |
CN100408554C (zh) | 高纯度肼基碳酸甲酯的合成新工艺 | |
CN114195720B (zh) | 一种依托咪酯的纯化方法 | |
CN113234015B (zh) | 一种3-酰基二氢喹啉衍生物及其制备方法和应用 | |
CN103739568B (zh) | 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法 | |
CN107188909B (zh) | 一种合成吲哚取代或二茂铁取代氮杂芳烃的方法 | |
CN106699724B (zh) | 一种自合成母液中回收盐酸阿替卡因或其中间产物的方法 | |
CN112939855B (zh) | 一种制备含有薁环结构的1,4-二氢吡啶衍生物的方法 | |
CN105622493B (zh) | 一种烯胺酮和醛串联反应合成全取代吡啶类化合物的方法 | |
CN112094220A (zh) | 一种3-砜甲基-1h-吲哚化合物的绿色合成方法 | |
CN113185507A (zh) | 一种鲁拉西酮制备方法 | |
CN112441961B (zh) | 一种3-吡咯琳-2-酮类化合物的合成方法 | |
CN103130702A (zh) | 一种合成3-取代吲哚和2,3-二取代吲哚的方法 | |
CN106967063A (zh) | 1‑三氟甲基‑1,2,3,4‑四氢‑β‑咔啉衍生物及其制备方法 | |
JP5419570B2 (ja) | 2−アセチルアミノメチル−4−(4−フルオロベンジル)モルホリンの精製方法 | |
CN116768749A (zh) | 一种甲氨蝶呤中间体的精制方法 | |
CN103936750B (zh) | 一种药物中间体吲哚类化合物的合成方法 | |
CN113861109A (zh) | 一种4-氯喹啉类化合物的合成方法 | |
JP2007230942A (ja) | 4−置換テトラヒドロピランの製造方法 | |
CN105061305A (zh) | 一步合成3-甲基-2-吡啶甲酸甲酯的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1166789 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1166789 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: TEIJIN LIMITED Free format text: FORMER OWNER: TEIJIN PHARMA LTD. Effective date: 20150417 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150417 Address after: Osaka City, Osaka of Japan Patentee after: TEIJIN Ltd. Address before: Tokyo, Japan Patentee before: Teijin Pharma Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140716 |
|
CF01 | Termination of patent right due to non-payment of annual fee |